Pharmaceuticals

Prolastin, Prolastin-C Market Forecast 2026–2035: Data Trends and Industry Insights

March 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the prolastin, prolastin-c market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Prolastin, Prolastin-C Market expected to grow between 2026 and 2030?

Historically, growth stemmed from the approval for alpha-1 antitrypsin deficiency, its clinical effectiveness in protecting the lungs, the acceptance by specialist pulmonologists, a lack of alternative treatments, and the availability of plasma-derived proteins.

Market growth during the forecast period is anticipated, driven by factors such as enhanced genetic screening rates, increasing awareness regarding alpha-1 antitrypsin deficiency, the proliferation of specialized care centers, a rising prevalence of respiratory diseases, and improved adherence to long-term therapies. Concurrently, significant trends expected in this period include the expanding utilization of alpha-1 replacement therapy, an increase in long-term lung protection treatments, a greater number of AAT deficiency diagnoses, the adoption of hospital-based augmentation therapy, and a concerted effort to halt disease progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19920&type=smp

Which Drivers Are Influencing Market Acceleration In The Prolastin, Prolastin-C Market?

A growing occurrence of respiratory illnesses is projected to fuel the expansion of the prolastin, prolastin-C market in the future. Such infections are conditions impacting the respiratory system, encompassing areas like the nose, throat, airways, and lungs. They stem from a range of causative agents, including viruses, bacteria, fungi, and other microbes. The escalation in respiratory infections is propelled by elements like novel viral strains, seasonal variations, compromised immune defenses, compounded by atmospheric contamination and greater human movement. Prolastin and Prolastin-C, which are both types of alpha-1 antitrypsin (AAT) replacement therapy, aid in treating respiratory conditions, especially chronic obstructive pulmonary disease (COPD) linked to alpha-1 antitrypsin deficiency. They achieve this by restoring the insufficient AAT protein, consequently diminishing lung inflammation, safeguarding against tissue damage from protease activity, and enhancing lung function and overall respiratory well-being for individuals with this genetic ailment. For example, data from October 2024, provided by the National Asthma Council, an Australia-based non-profit organization, indicated that Australia registered a total of 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This number is nearly identical to the 473 asthma-related deaths documented in 2022, emphasizing a stable pattern in asthma fatalities across these two years. Consequently, the rising frequency of respiratory infections is stimulating expansion within the prolastin, prolastin-C market.

What Leading Segments Are Studied In The Prolastin, Prolastin-C Market?

The prolastin, prolastin-c market covered in this report is segmented –

1) By Type: 20ml, 40ml

2) By Indication: Alpha-1 Antitrypsin Deficiency, Respiratory Health, Chronic Lung Disease, Genetic Disorders

3) By Application: Hospital, Pharmacy

Which Trends Are Influencing The Development Of The Prolastin, Prolastin-C Market?

Companies prominently engaged in the peolastin and prolastin-C market are prioritizing clinical trials to evaluate the safety and efficacy of pharmaceutical products. These research studies are designed to assess the safety, effectiveness, and any adverse reactions of novel treatments, medicines, or medical devices involving human subjects. For example, in July 2023, Grifols SA, a pharmaceutical firm based in Spain, reported achieving its enrollment goal of 339 patients for the SPARTA (Study of ProlAstin-c Randomized Therapy with Alpha-1 Augmentation) phase 3 clinical trial. The trial seeks to determine if individuals with emphysema suffering from alpha-1-antitrypsin (AAT) deficiency (alpha-1) experience a slower progression of lung tissue deterioration when administered weekly treatment using two distinct dose regimens of Grifols Prolastin-C. The overarching goal is to evaluate Prolastin-C’s effectiveness in mitigating emphysema progression in alpha-1 antitrypsin deficiency (AATD) patients. This is achieved by elevating AAT protein levels through weekly delivery of two active doses (60 and 120 mg/kg) when compared against a placebo.

Which Leading Companies Dominate The Prolastin, Prolastin-C Market Share?

Major companies operating in the prolastin, prolastin-c market are Grifols SA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prolastin-prolastin-c-global-market-report

How Does The Prolastin, Prolastin-C Market Perform Across Major Global Regions?

North America was the largest region in the prolastin or prolastin-C market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prolastin, prolastin-c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prolastin, Prolastin-C Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19920&type=smp

Browse Through More Reports Similar to the Global Prolastin, Prolastin-C Market 2026, By The Business Research Company

Proanthocyanidins Market Report 2026

https://www.thebusinessresearchcompany.com/report/proanthocyanidins-global-market-report

Isotretinoin Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/isotretinoin-drugs-global-market-report

Retinol Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinol-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795